Metronomic Capecitabine with Camrelizumab and Apatinib Mesylate for Treatment of Advanced Pancreatic Cancer

NCT06759090 | Not Yet Recruiting Phase 2

• 1 other identifier: mCIV-PC-01
• Study Type: interventional
• Target: 43
• Locations: 1 country
• Sites: 1

Brief Summary

This study is a multicenter, single-arm, phase II exploratory study, aims to evaluate the efficacy and safety of metronomic capecitabine with camrelizumab and apatinib mesylate in advanced pancreatic cancer after the failure of first-line treatment.

Conditions

Metastatic Pancreatic Carcinoma

Keywords

Metronomic chemotherapy

Outcome Measures

Primary Outcomes (3)

• Objective Response Rate (ORR)

  The proportion of patients who had tumor evaluated as CR/PR according to irRECIST1.1 criteria during the whole study.

  Up to 18 months

• Disease Control Rate (DCR)

  The proportion of patients who had tumor evaluated as CR/PR/SD according to irRECIST1.1 criteria during the whole study.

  Up to 18 months

• Safety of treatment

  Evaluate the grading of blood test abnormalities and other adverse drug reaction according to CTCAE 5.0.

  Up to 18 months

Secondary Outcomes (4)

• The quality of life

  Up to 18 months

• Overall Survival (OS)

  Up to 18 months

• Progression-free Survival (PFS)

  Up to 18 months

• Response Rate of CA199

  Up to 18 months

Study Arms (1)

Arm A

EXPERIMENTAL

Metronomic capecitabine: 650 mg/m2, twice daily, to be swallowed with water within 30 minutes after a meal; Camrelizumab: 200 mg, intravenous injection once every 2 weeks; Apatinib mesylate: 250mg, once daily, to be swallowed with water within 30 minutes after a meal;

Drug: Metronomic capecitabine; Drug: Camrelizumab; Drug: Apatinib Mesylate Tablets

Interventions

Metronomic capecitabine DRUG

Metronomic capecitabine: 650 mg/m2, twice daily, to be swallowed with water within 30 minutes after a meal;

Arm A

Camrelizumab DRUG

Camrelizumab: a PD-1 inhibitor, 200 mg, intravenous injection once every 2 weeks;

Arm A

Apatinib Mesylate Tablets DRUG

Apatinib mesylate: a small molecule of tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor 2 (VEGFR-2) , 250mg, once daily, to be swallowed with water within 30 minutes after a meal.

Arm A

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• : Age is 18 years or older; 2: Pathologically confirmed pancreatic adenocarcinoma; 3: As determined by the investigator, second-line treatment for advanced pancreatic cancer has failed; or the patient has a poor performance status (PS score \>1), and the investigator considers that the patient cannot tolerate a second-line regimen with two or more drugs.
• : Performance status PS score 0-2; 5: Expected survival period \>= 3 months; 6: According to the RECIST1.1 criteria, the patient has at least one measurable lesion present; 7: Good organ function levels: • ANC\>=1.5×10\^9/L; • PLT\>=75×10\^9/L; • Hb\>=80 g/L; • TBIL\<=1.5×ULN; • ALT and AST\<=3×ULN; For patients with liver metastases, ALT and AST\<=5×ULN; • Cr\<=1.5×ULN, if Cr\>1.5×ULN, then Ccr\>50ml/min (calculated by Cockcroft-Gault formula); • LVEF\>=50%; • Fridericia corrected QT interval (QTcF) \<450 ms for males, \<470 ms for females.
• : After assessment by the researcher, the participant is able to comply with the trial protocol; 9: Voluntarily participate in this clinical trial, understand the research procedures, and can sign the informed consent form in writing;

You may not qualify if:

• : Patients who have developed resistance after treatment with capecitabine and apatinib are not recommended for enrollment unless more than 6 months have passed since the last dose, in which case they can continue to challenge its use; patients who have previously undergone immunotherapy (regardless of whether or not they used camrelizumab) can cross-line use or switch to camrelizumab to continue challenging its use.
• : Received chemotherapy, radiotherapy, immunotherapy, biologics, or endocrine therapy for anti-tumor treatment, or other investigational drugs not yet on the market within 4 weeks before the first use of the study drug; 3: Within 4 weeks before the first use of the study drug, the subject has undergone major organ surgery (excluding biopsy) or experienced significant trauma, or requires elective surgery during the trial period; 4: Use of steroid hormones (prednisone equivalent) greater than 20 mg/day for more than 14 consecutive days within 14 days before the first use of the study drug; 5: Adverse reactions from previous anti-tumor treatments have not yet recovered to CTCAE 5.0 grade \<=1 (excluding alopecia and other toxicities determined by the investigator to pose no safety risk).
• : Past or current retinal vein occlusion (RVO) or high-risk factors (such as uncontrolled glaucoma or high intraocular pressure, history of hyper-viscous blood syndrome or hypercoagulable state); 7: History of active major bleeding; 8: Uncontrolled hypertension; 9: Severe unhealed wounds or fractures; 10: Ulcer, bowel perforation or intestinal obstruction; 11: After evaluation by researchers, there are contraindications for drug prophylaxis of thromboembolism; 12: Central nervous system metastasis, leptomeningeal metastasis; 13: Past medical history or physical examination reveals central nervous system diseases, except for those that have been adequately treated (such as primary brain tumors, uncontrolled seizures, or stroke); 14: Active viral, bacterial, or fungal infections requiring systemic treatment (such as pneumonia); 15: Has a history of active tuberculosis; 16: A history of immunodeficiency, including HIV test positive, or other acquired, congenital immunodeficiency diseases, or a history of organ transplantation, or allogeneic bone marrow transplantation, or autologous hematopoietic stem cell transplantation; 17: Had active autoimmune diseases requiring systemic treatment within the past 2 years; 18: Vaccination within 30 days before treatment, including intranasal influenza vaccine, except for seasonal influenza vaccine; 19: Within 3 months prior to treatment, there were cardiovascular diseases, including: unstable angina; clinically significant or drug-treated malignant arrhythmias; myocardial infarction; Class III-IV heart failure; transient ischemic attack; thromboembolic events (such as deep vein thrombosis, pulmonary embolism, etc.), and any other cardiac conditions deemed by the investigator as unsuitable for participation in this trial.
• : Pre-cancerous blood disorders, such as myelodysplastic syndromes; 21: Clinical history of or pre-existing interstitial lung disease, such as non-infectious pneumonia or pulmonary fibrosis, or evidence of interstitial lung disease found on baseline chest CT scan; 22: Positive baseline pregnancy test in female patients who are pregnant, breastfeeding, or have childbearing potential; 23: Patients who have had other primary malignant tumors within the past 5 years, except for locally curable tumors (such as basal or squamous cell carcinoma of the skin, superficial bladder cancer, cervical or breast carcinoma in situ) can be enrolled after a definitive cure.
• : May be allergic to any of the drug ingredients; 25: According to the investigator's judgment, there are other serious conditions that endanger patient safety or affect the patient's ability to complete the study, or other reasons that make the patient unsuitable for participation in this clinical trial;

Sponsors & Collaborators

• Zhejiang University: lead

Study Sites (1)

The First Affiliated Hospital, Zhejiang University School of Medicine

Hangzhou, Zhejiang, 310003, China

Location

MeSH Terms

Conditions

Pancreatic Neoplasms

Interventions

camrelizumab; apatinib

Condition Hierarchy (Ancestors)

Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Endocrine Gland Neoplasms; Digestive System Diseases; Pancreatic Diseases; Endocrine System Diseases

Central Study Contacts

Ming Chen, Doctor.

CONTACT

0571-87236557; zychenming@zju.edu.cn

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: The chairman of the First Affiliated Hospital of Zhejiang University School of Medicine

Study Record Dates

• First Submitted: December 29, 2024
• First Posted: January 6, 2025
• Study Start: January 15, 2025
• Primary Completion (Estimated): January 15, 2027
• Study Completion (Estimated): June 15, 2028
• Last Updated: January 6, 2025

Record last verified: 2024-12

Locations

CN (1)